Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.

@article{GaillardMoguilewsky1991PharmacologyOA,
  title={Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.},
  author={M. Gaillard-Moguilewsky},
  journal={Urology},
  year={1991},
  volume={37 2 Suppl},
  pages={
          5-12
        }
}
Antiandrogens are compounds able to block the effect of androgens directly on their target cells by inhibiting their binding to the androgen receptor (AR). Two chemical classes of antiandrogens are presently on the market or in clinical trials: steroids (cyproterone, megestrol acetates), and nonsteroids (flutamide, nilutamide). Steroid antiandrogens interact not only with AR but also with progestin and glucocorticoid receptors and thus give rise to progestin and glucocorticoid effects. By… Expand
Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection.
TLDR
It is observed that, although flutamide and cyproterone acetate blocked androgen-induced gene expression, they failed to inhibit DHT protection against apoptotic insults in cultured hippocampal neurons, suggesting a role for AR in the agonist effects of antiandrogens. Expand
Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.
TLDR
The current state of anti-androgen therapy, mainly for CRPC, is detailed, with major emphasis on the most potent and promising compounds under development. Expand
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma
TLDR
Proper stratification of patients at entry into such studies with documentation of various prognostic factors will add statistical value and enable physicians to draw better conclusion on the relative efficacy of these agents. Expand
In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring.
TLDR
Novel selective androgen receptor modulators with improved in vivo pharmacological activity can be designed and synthesized based on the structure-activity relationship identified in these studies. Expand
New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer
TLDR
An overview of the structure of human AR and its key structural domains that can be used as targets to develop novel antiandrogens is provided. Expand
Impact level of dihydrotestosterone on the hypothalamic-pituitary-leydig cell axis in men.
TLDR
Data show that DHT exerts no direct action on the pituitary to retroregulate LH secretion and to modify either B/I LH ratio or FAS secretion, and its reducing effect on LH secretion is likely mediated at the hypothalamic level. Expand
Discovery and therapeutic promise of selective androgen receptor modulators.
TLDR
The recent discovery of nonsteroidal selective androgens receptor modulators (SARMs) provides a promising alternative for testosterone replacement therapies with advantages including oral bioavailability, flexibility of structural modification, androgen receptor specificity, tissue selectivity, and the lack of steroid-related side effects. Expand
Antiandrogens in Prostate Cancer
TLDR
Some Aspects of the Molecular Endocrinology of Prostatic Cancer are studied. Expand
In utero exposure to antiandrogens alters the responsiveness of the prostate to p,p'-DDE in adult rats and may induce prostatic inflammation.
TLDR
In utero antiandrogen treatments produced a latent effect on prostate growth that became pronounced only in the postpubertal stage, suggesting the possible linkage between in uteroAntiandrogen treatment and prostatic inflammation needs to be further evaluated. Expand
Orchiectomy or androgen receptor blockade attenuates baroreflex-mediated bradycardia in conscious rats
TLDR
The data suggest that androgen depletion or adequate androgen receptor blockade attenuates baroreflex bradycardia and the reflex increase in serum testosterone may counterbalance the action of the lower doses of flutamide. Expand
...
1
2
...

References

SHOWING 1-10 OF 35 REFERENCES
Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
TLDR
Animal experiments confirm that anandron can counteract the effect of adrenal androgens and inhibit the LHRH analog-induced initial increase in androgen ("flare-up") and decrease prostate weight in rats castrated either surgically or by buserelin or DES. Expand
The pure antiandrogen ru 23908 (anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review
The nonsteroidal antiandrogen RU 23908 (AnandronR) weakly interacts with the prostatic cytosolic androgen receptor and shows a fast dissociation rate. When administered to immature castrated rats upExpand
Biological aspects of antiandrogens.
TLDR
A comparative study in castrated rats revealed that flutamide was equipotent to cyproterone acetate (CPA) as an antiandrogen, and these potencies were substantiated by a newly developed assay measuring DNA synthesis rate. Expand
An investigation into the anti-androgenic properties of the non-steroidal compound, SCH 13521 (4'-nitro-3'-trifluoromethylisobutyrylanilide).
TLDR
It is concluded that this non-steroidal anti-androgen measured under conditions in vivo as against in vitro may have to undergo obligatory metabolism to a more active compound before its anti- androgenic properties are manifest. Expand
Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate
TLDR
The present data show that cyproterone acetate and megestrol acetate, in addition to their well-known progestational and glucocorticoid action, have intrinsic androgenic activity. Expand
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
TLDR
The effects of the s.c. administration of a depot formulation of the luteinizing hormone-releasing hormone (LHRH) analogue Zoladex were studied in normal male rats to investigate whether these antiandrogens might prevent the LHRH-A-induced initial increase in these parameters. Expand
Combined long‐term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat
TLDR
The present data show that blockage of the Δ4‐steroidogenic pathway induced by treatment with an LHRH agonist prevents the escape phenomenon observed during long‐term treatment with a pure antiandrogen, and permits maximal inhibitory effects of the two treatments on secondary sex organ weight. Expand
Steroid hormone receptors and pharmacology.
TLDR
Highly specific ligands derived from this screening system are being used not only as drugs but as tools to study the physiological regulation of hormone receptors in both peripheral and central target tissues. Expand
The Antiandrogen Anandron Potentiates the Castrating Effect of the LH‐RH Agonist Buserelin in the Rat
TLDR
The addition of Anandron to LH-RH agonist treatment would not only counter flare-up and adrenal androgen effects on the prostate but would also lower the doses of peptide or the time required for chemical castration. Expand
Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues.
Abstract RU 23908 (5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione) is a non-steroid anti-androgen with potent peripheral and central activity. In the rat, it inhibitsExpand
...
1
2
3
4
...